Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Ashley Muller

1PUBLICATIONS
4CO-AUTHORS
Metabolic medicine
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (1)

Sort by Publication Date:
|Aug 26, 2024
Ocrelizumab alters the circulating metabolome in people with relapsing-remitting multiple sclerosis.

Fatemeh Siavoshi, Dimitrios C Ladakis, Ashley Muller

Pageof 1

Frequent Collaborators

1 joint publications

Fatemeh Siavoshi

1 joint publications

Dimitrios C Ladakis

1 joint publications

Bardia Nourbakhsh

1 joint publications

Pavan Bhargava

Frequent Collaborators

1 joint publications

Fatemeh Siavoshi

1 joint publications

Dimitrios C Ladakis

1 joint publications

Bardia Nourbakhsh

1 joint publications

Pavan Bhargava

Top Related Videos

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on : Oct 15, 2017

8.3K
See more related videos

Top Related Videos

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on : Oct 15, 2017

8.3K
See more related videos